Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 20/20 | 0.77 |
| ▸ | NR4A2 | P43354 | 9/20 | 0.67 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.67 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.67 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.67 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25838107 | 0.88 | DHODH (0.67) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL14452168 | 0.88 | DHODH (0.85) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL517489 | 0.87 | DHODH (1.00) | DHODHNR4A2 | |
| SCHEMBL20673315 | 0.86 | DHODH (0.78) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL31125355 | 0.86 | DHODH (1.00) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL20673194 | 0.83 | DHODH (0.56) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL25838236 | 0.81 | DHODH (0.64) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| Vidofludimus SCHEMBL247888 | 0.80 | DHODH (1.00) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| Vidofludimus SCHEMBL29352865 | 0.80 | DHODH (1.00) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| Vidofludimus SCHEMBL28974266 | 0.80 | DHODH (0.98) | DHODHNR4A2JMJD7NR4A1NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015154820-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | PANOPTES PHARMA GMBH (AT) | 2015-10-15 | — | — | WO | claimed |
| US-8354433-B2 | Anti-inflammatory agents as virostatic compounds | 4SC AG (DE) | 2013-01-15 | — | — | US | claimed |
| US-20230285355-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | KIORA PHARMACEUTICALS GMBH (AT) | 2023-09-14 | — | — | US | disclosed |
| US-20230285355-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | KIORA PHARMACEUTICALS GMBH (AT) | 2023-09-14 | — | — | US | disclosed |
| US-11730716-B2 | Compounds for treating ophthalmic diseases and disorders | KIORA PHARMACEUTICALS GMBH (AT) | 2023-08-22 | — | — | US | disclosed |
| US-11730716-B2 | Compounds for treating ophthalmic diseases and disorders | KIORA PHARMACEUTICALS GMBH (AT) | 2023-08-22 | — | — | US | disclosed |
| EP-2427186-B1 | DIHYDROOROTATE-DEHYDROGENASEE INHIBITORS AS VIROSTATIC COMPOUNDS | PANOPTES PHARMA GES M B H (AT) | 2022-01-12 | — | — | EP | disclosed |
| US-20210088520-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | SERVIER PHARMACEUTICALS LLC | 2021-03-25 | — | — | US | disclosed |
| US-9795590-B2 | Anti-inflammatory agents as virostatic compounds | PANOPTES PHARMA GMBH (AT) | 2017-10-24 | — | — | US | disclosed |
| US-9795590-B2 | Anti-inflammatory agents as virostatic compounds | PANOPTES PHARMA GMBH (AT) | 2017-10-24 | — | — | US | disclosed |
| US-9795590-B2 | Anti-inflammatory agents as virostatic compounds | PANOPTES PHARMA GMBH (AT) | 2017-10-24 | — | — | US | disclosed |
| US-20120028985-A1 | COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028985-A1 | COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028985-A1 | COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2012-02-02 | — | — | US | disclosed |
| EP-2362771-A1 | COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2011-09-07 | — | — | EP | disclosed |
| US-20100280081-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | 4SC AG (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280081-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | 4SC AG (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280081-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | 4SC AG (DE) | 2010-11-04 | — | — | US | disclosed |
| WO-2010052027-A1 | COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010052027-A1 | COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028985-A1 | COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE | HLA-DRB1, IL2, SSB | DHODH 2305/4885NR4A2 2709/4885JMJD7 2523/4885 |
| US-11730716-B2 | Compounds for treating ophthalmic diseases and disorders | DHODH, ALDH1A2, QDPR | DHODH 1/4885NR4A2 3111/4885JMJD7 4389/4885 |
| US-20210088520-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | DHODH, IDH1, IDH3A | DHODH 1/4885NR4A2 3748/4885JMJD7 1633/4885 |
| US-20230285355-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | DHODH, ALDH1A2, QDPR | DHODH 1/4885NR4A2 3111/4885JMJD7 4389/4885 |
| US-20100280081-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | TNF, MIF, IL1B | DHODH 2796/4885NR4A2 2483/4885JMJD7 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.